<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03881501</url>
  </required_header>
  <id_info>
    <org_study_id>TJCC009</org_study_id>
    <nct_id>NCT03881501</nct_id>
  </id_info>
  <brief_title>Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma</brief_title>
  <official_title>A Single Arm, Observational Clinical Trial to Evaluate the Efficacy and Safety of Combination Treatment With Sintilimab Injection Plus Endostar in Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a a single arm, observational clinical trial to evaluate the efficacy and safety of
      combination treatment with sintilimab injection plus endostar in untreated locally advanced
      or metastatic hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For the first line treatment with untreated locally advanced or metastatic hepatocellular
      carcinoma, sintilimab injection plus endostar might be one of the treatment choices.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2019</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The rate of participants that achieve either a complete response (CR) or a partial response (PR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>up to 3 years</time_frame>
    <description>From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Overall survival is defined as time from the start of treatment until death due to any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The time between the first recorded and objective remission to the first onset of disease progression or all-cause death (whichever happens first)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as measured by number and grade of adverse events</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Summary adverse events according to NCI-CTCAE 4.03</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2</enrollment>
  <condition>Hepatocellular Carcinoma Non-resectable</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able and willing to comply with the study plans in this protocol and sign the informed
             consent;

          2. Age of 18-75 years;

          3. Cytological or histological diagnosis of untreated locally advanced or metastatic
             hepatocellular carcinoma;

          4. Diseases are not suitable for radical surgery and/or local treatment, or disease
             progression occurs after surgery and/or local treatment;

          5. At least one measurable lesion as defined by RECIST 1.1 criteria and untreated lesion;

          6. Patients who have received previous local treatment (e.g., radiofrequency ablation,
             ethanol or acetic acid injection, cryoablation, high intensity focused ultrasound,
             transcatheter arterial chemoembolization, transcatheter arterial embolization, etc.)
             are eligible to participate in the study if the target lesion has not received local
             treatment before, or if the target lesion within the scope of local treatment has
             subsequently developed on the basis of RECIST v1.1;

          7. ECOG performance status of 0-1;

          8. Child-Pugh A;

          9. Bone marrow function: absolute neutrophil count(ANC) ≥1.5×109 /L, platelet count(PLT)
             ≥75×109 /L, hemoglobin(HB) ≥90 g/L;

         10. alanine glutamate transaminase (ALT) and glutamate transaminase (AST) ≤5 x upper limit
             of normal range (ULN);total bilirubin (TBIL)≤3 x upper limit of normal range
             (ULN);Creatinine(Cr)≤1.5 x upper limit of normal range(ULN);Serum albumin (&gt; 28 g/L)
             (2.8 g/dL);Patients not receiving anticoagulation therapy: INR or aPTT &lt; 2
             *ULN;Urinary cellulose test paper results Proteinuria &lt; 2 (7 days before the start of
             treatment);Patients with baseline cellulose test paper urine test results (&gt; 2
             proteinuria) should collect 24-hour urine, and then must confirm that the 24-hour
             urinary protein content is less than 1 g;

         11. HIV test results were negative at screening;

         12. Records of virological status of hepatitis, confirmed by serological tests of HBV and
             HCV;

         13. Patients with active hepatitis B virus (HBV) infection:HBV DNA &lt; 500 IU/mL was
             obtained within 28 days before the start of the study, and received at least 14 days
             of anti-HBV treatment (based on local standard treatment, such as entecavir) prior to
             the study, and was willing to continue treatment during the study period.

        Exclusion Criteria:

          1. Systemic HCC treatment has been received in the past;

          2. History of primary immunodeficiency is known;

          3. It is known to have active tuberculosis;

          4. History of allogeneic organ transplantation and hematopoietic stem cell
             transplantation is known;

          5. It is known that there is a history of human immunodeficiency virus (HIV) infection
             (that is, HIV antibody positive);

          6. Severe allergic/allergic reactions to humanized antibodies or fusion proteins were
             observed;

          7. It is known to have hypersensitivity to any component contained in Endor preparations;

          8. Initial serious heart disease patients include congestive heart failure,
             uncontrollable high-risk arrhythmia, unstable angina pectoris, myocardial infarction,
             severe valvular disease and refractory hypertension;

          9. History of PIA meningitis;

         10. Major cardiovascular diseases (e.g. New York Heart Association Grade II or more
             serious heart disease, myocardial infarction or cerebrovascular accident), unstable
             arrhythmia or unstable angina pectoris, occurred within three months before the start
             of treatment;

         11. Major surgical treatments (except diagnosis) were received within 4 weeks before the
             start of the study, or major surgical treatments were expected during the study
             period;

         12. Other malignant tumors were diagnosed within 5 years before the first administration.
             Exceptions included radical basal cell carcinoma, squamous cell carcinoma, adequately
             treated cervical cancer in situ, and localized prostate cancer;

         13. Active infections requiring systemic treatment;

         14. Fiberboard HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC are known;

         15. Moderate or severe ascites;

         16. History of hepatic encephalopathy;

         17. Patients with a history of HCV infection but negative results of HCV RNA PCR may
             consider that they are not infected with HCV;

         18. Systemic glucocorticoid therapy or any other form of immunosuppressive therapy is
             being administered within 7 days prior to the diagnosis of immunodeficiency or the
             study's first administration; physiological doses of glucocorticoid (&lt;10mg/day
             prednisone or equivalent) are allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xianglin Yuan, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Tongji Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xianglin Yuan, MD,PhD</last_name>
    <phone>8627-83663406</phone>
    <email>xlyuan1020@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yanmei Zou, MD,PhD</last_name>
    <phone>8627-83663406</phone>
    <email>zouyanmei0101@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xianglin Yuan, MD,PHD</last_name>
      <phone>8627-83663406</phone>
      <email>xlyuan1020@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yanmei Zou, MD,PHD</last_name>
      <phone>8627-83663406</phone>
      <email>zouyanmei0101@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>March 16, 2019</last_update_submitted>
  <last_update_submitted_qc>March 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Xianglin Yuan</investigator_full_name>
    <investigator_title>Professor, Head of the cancer center</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Sintilimab Injection</keyword>
  <keyword>Endostar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

